{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:46:45Z","timestamp":1777538805056,"version":"3.51.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004681","name":"Higher Education Commission Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011039","name":"Swiss Centre for Applied Human Toxicology","doi-asserted-by":"publisher","award":["2021-2024"],"award-info":[{"award-number":["2021-2024"]}],"id":[{"id":"10.13039\/501100011039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.taap.2024.116945","type":"journal-article","created":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T17:45:39Z","timestamp":1714326339000},"page":"116945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1"],"prefix":"10.1016","volume":"486","author":[{"given":"Jacek","family":"K\u0119dzierski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Christin","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Odermatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Smie\u0161ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2024.116945_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.04.007","article-title":"Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11\u03b2-hydroxylase and aldosterone synthase","volume":"192","author":"Akram","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834016642370","article-title":"CYP17 inhibitors in prostate cancer: latest evidence and clinical potential","volume":"8","author":"Alex","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0022-4731(89)90384-1","article-title":"Inhibition of human adrenal steroidogenic enzymes in vitro by imidazole drugs including ketoconazole","volume":"32","author":"Ayub","year":"1989","journal-title":"J. Steroid Biochem."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0020","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-16-0661","article-title":"Evolution of the mineralocorticoid receptor: sequence, structure and function","volume":"234","author":"Baker","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.taap.2024.116945_bb0025","first-page":"1752","article-title":"Integrated modeling program","volume":"26","author":"Banks","year":"2005","journal-title":"Applied Chemical Theory (IMPACT). J. Comput. Chem."},{"issue":"6","key":"10.1016\/j.taap.2024.116945_bb0030","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1210\/endo-101-6-1676","article-title":"Danazol inhibits steroidogenesis in the rat testis in vitro","volume":"101","author":"Barbieri","year":"1977","journal-title":"Endocrinology"},{"key":"10.1016\/j.taap.2024.116945_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111168","article-title":"Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess","volume":"524","author":"Beck","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.taap.2024.116945_bb0040","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.bcp.2017.01.010","article-title":"Inhibition of 11\u03b2-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole","volume":"130","author":"Beck","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2024.116945_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jsbmb.2017.03.008","article-title":"Virtual screening applications in short-chain dehydrogenase\/reductase research","volume":"171","author":"Beck","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.taap.2024.116945_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2020.105605","article-title":"Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals","volume":"199","author":"Beck","year":"2020","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.taap.2024.116945_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104311","article-title":"Drug-induced endocrine blood pressure elevation","volume":"154","author":"Beck","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.taap.2024.116945_bb0060","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nchem.1243","article-title":"Quantifying the chemical beauty of drugs","volume":"4","author":"Bickerton","year":"2012","journal-title":"Nat. Chem."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0065","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/030089169408000406","article-title":"R75251 in prostate cancer patients in progression after first-line hormonal treatment","volume":"80","author":"Boccardo","year":"1994","journal-title":"Tumori"},{"key":"10.1016\/j.taap.2024.116945_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/srep29468","article-title":"Promising tools in prostate Cancer research: selective non-steroidal cytochrome P450 17A1 inhibitors","volume":"6","author":"Bonomo","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.taap.2024.116945_bb0075","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1517\/13543784.2011.577737","article-title":"Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor","volume":"20","author":"Boumber","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0080","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/pros.2990160409","article-title":"R 75251, a new inhibitor of steroid biosynthesis","volume":"16","author":"Bruynseels","year":"1990","journal-title":"Prostate"},{"key":"10.1016\/j.taap.2024.116945_bb0085","series-title":"Nonclinical Evaluation of Endocrine-Related Drug Toxicity Guidance for Industry Nonclinical Evaluation of Endocrine-Related Drug Toxicity Guidance for Industry","volume":"10","author":"Center for Drug Evaluation and Research","year":"2015"},{"issue":"1\u20136","key":"10.1016\/j.taap.2024.116945_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0960-0760(95)00230-8","article-title":"P450-dependent enzymes as targets for prostate cancer therapy","volume":"56","author":"De Coster","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0959-8049(97)10120-4","article-title":"Early clinical experience with liarozole (Liazal(TM)) in patients with progressive prostate cancer","volume":"34","author":"Denis","year":"1998","journal-title":"Eur. J. Cancer"},{"issue":"7383","key":"10.1016\/j.taap.2024.116945_bb0100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001","volume":"482","author":"Devore","year":"2012","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.taap.2024.116945_bb0105","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-20-4618","article-title":"A surgical window trial evaluating medroxyprogesterone acetate with or without entinostat in patients with endometrial cancer and validation of biomarkers of cellular response","volume":"27","author":"Duska","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.taap.2024.116945_bb0110","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1021\/acs.jmedchem.8b00419","article-title":"Structure-based Design of Inhibitors with improved selectivity for steroidogenic cytochrome P450 17A1 over cytochrome P450 21A2","volume":"61","author":"Fehl","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0115","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.taap.2024.116945_bb0120","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.taap.2024.116945_bb0125","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.taap.2024.116945_bb0130","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1021\/ci3002342","article-title":"Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors\/antiandrogens for prostate cancer therapy","volume":"52","author":"Gianti","year":"2012","journal-title":"J. Chem. Inf. Model."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12210-016-0565-z","article-title":"Heme iron centers in cytochrome P450: structure and catalytic activity","volume":"28","author":"Gilardi","year":"2017","journal-title":"Rendiconti Lincei"},{"issue":"21","key":"10.1016\/j.taap.2024.116945_bb0140","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2006.08.4046","article-title":"Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin","volume":"25","author":"Gish","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1006320122711","article-title":"Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer","volume":"59","author":"Goss","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.taap.2024.116945_bb0150","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1006480504790","article-title":"Liarozole fumarate (R85246): in the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer","volume":"64","author":"Goss","year":"2000","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.taap.2024.116945_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1107\/S2052520616003954","article-title":"The Cambridge structural database","volume":"72","author":"Groom","year":"2016","journal-title":"Acta Crystallogr. Sect. B: Struct. Sci. Cryst. Eng. Mater."},{"key":"10.1016\/j.taap.2024.116945_bb0160","series-title":"Cytochrome P450: Structure, Mechanism, and Biochemistry","first-page":"523","article-title":"Human cytochrome P450 enzymes","author":"Guengerich","year":"2015"},{"key":"10.1016\/j.taap.2024.116945_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103462","article-title":"Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors","volume":"94","author":"Gumede","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"Pt B","key":"10.1016\/j.taap.2024.116945_bb0170","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jsbmb.2014.10.009","article-title":"Adrenocortical endocrine disruption","volume":"155","author":"Harvey","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"9","key":"10.1016\/j.taap.2024.116945_bb0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/ard.53.9.619-c","article-title":"Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? [4]","volume":"53","author":"Hopkinson","year":"1994","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0180","first-page":"111","article-title":"Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days","volume":"5","author":"Hughes","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.taap.2024.116945_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147731","article-title":"Retinoids as chemo-preventive and molecular-targeted anti-cancer therapies","volume":"22","author":"Hunsu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2024.116945_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.crtox.2023.100119","article-title":"Characterization of the interferences of systemic azole antifungal drugs with adrenal steroid biosynthesis using H295R cells and enzyme activity assays","volume":"5","author":"J\u00e4ger","year":"2023","journal-title":"Current Research in Toxicology"},{"key":"10.1016\/j.taap.2024.116945_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116638","article-title":"Virtual screening and biological evaluation to identify pharmaceuticals potentially causing hypertension and hypokalemia by inhibiting steroid 11\u03b2-hydroxylase","volume":"475","author":"J\u00e4ger","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2024.116945_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2023.111929","article-title":"Extended steroid profiling in H295R cells provides deeper insight into chemical-induced disturbances of steroidogenesis: exemplified by prochloraz and anabolic steroids","volume":"570","author":"J\u00e4ger","year":"2023","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0205","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.bmc.2007.10.094","article-title":"Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17\u03b1-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure","volume":"16","author":"Jagusch","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10637-006-9003-x","article-title":"Phase II trial of nolatrexed dihydrochloride [Thymitaq\u2122, AG 337] in patients with advanced hepatocellular carcinoma","volume":"25","author":"Jhawer","year":"2007","journal-title":"Investig. New Drugs"},{"issue":"2","key":"10.1016\/j.taap.2024.116945_bb0215","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/jpet.113.11er13","article-title":"Erratum: the novel anti-cancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1 (journal of pharmacology and experimental therapeutics (2013) 346 (381-392))","volume":"347","author":"Jones","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"19","key":"10.1016\/j.taap.2024.116945_bb0220","doi-asserted-by":"crossref","first-page":"9695","DOI":"10.1080\/07391102.2022.2145497","article-title":"Friedelin, a novel inhibitor of CYP17A1 in prostate cancer from Cassia tora","volume":"41","author":"Joshi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"12","key":"10.1016\/j.taap.2024.116945_bb0225","doi-asserted-by":"crossref","first-page":"22799","DOI":"10.3390\/molecules201219880","article-title":"Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases","volume":"20","author":"Kaserer","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.taap.2024.116945_bb0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/CE.S49629","article-title":"Luliconazole for the treatment of fungal infections: an evidence-based review","volume":"9","author":"Khanna","year":"2014","journal-title":"Core Evidence"},{"issue":"8","key":"10.1016\/j.taap.2024.116945_bb0235","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1021\/ci300604z","article-title":"Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise","volume":"53","author":"Koes","year":"2013","journal-title":"J. Chem. Inf. Model."},{"issue":"9","key":"10.1016\/j.taap.2024.116945_bb0240","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1535-7163.MCT-10-0337","article-title":"The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias","volume":"9","author":"Kojima","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.taap.2024.116945_bb0245","doi-asserted-by":"crossref","first-page":"e2136","DOI":"10.1002\/onco.13957","article-title":"Phase I study of Entinostat in combination with enzalutamide for treatment of patients with metastatic castration-resistant prostate Cancer","volume":"26","author":"Lin","year":"2021","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.taap.2024.116945_bb0250","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1097\/CM9.0000000000000407","article-title":"Anabolic-androgenic steroids and cardiovascular risk","volume":"132","author":"Liu","year":"2019","journal-title":"Chin. Med. J."},{"issue":"3","key":"10.1016\/j.taap.2024.116945_bb0255","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"Madhavi Sastry","year":"2013","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.taap.2024.116945_bb0260","article-title":"Ketoconazole and liarozole in the treatment of advanced prostatic cancer","volume":"71(3 S):1068\u20131073","author":"Mahler","year":"1993","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.taap.2024.116945_bb0265","first-page":"1245","article-title":"Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines","volume":"15","author":"McGuire","year":"1999","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.taap.2024.116945_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2017.02.003","article-title":"When the guardian sleeps: reactivation of the p53 pathway in cancer","volume":"773","author":"Merkel","year":"2017","journal-title":"Mutat. Res. Rev. Mutat. Res."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0275","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0280","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s002800050982","article-title":"A multi-Centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma","volume":"44","author":"Mok","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.taap.2024.116945_bb0285","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1096\/fasebj.10.7.8635685","article-title":"Structural flexibility and functional versatility of mammalian P450 enzymes","volume":"10","author":"Negishi","year":"1996","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0290","article-title":"Structure-based discovery of selective CYP17A1inhibitors for castration-resistant prostate cancer treatment","volume":"7","author":"Omoboyowa","year":"2022","journal-title":"Biol. Meth. Prot."},{"issue":"10","key":"10.1016\/j.taap.2024.116945_bb0295","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-018-0077-y","article-title":"The role of ketoconazole in current prostate cancer care","volume":"15","author":"Patel","year":"2018","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.taap.2024.116945_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113781","article-title":"Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis","volume":"172","author":"Patt","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"31","key":"10.1016\/j.taap.2024.116945_bb0305","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1021\/acs.biochem.6b00532","article-title":"Cytochrome b5 activates the 17,20-Lyase activity of human cytochrome P450 17A1 by increasing the coupling of NADPH consumption to androgen production","volume":"55","author":"Peng","year":"2016","journal-title":"Biochemistry"},{"issue":"47","key":"10.1016\/j.taap.2024.116945_bb0310","doi-asserted-by":"crossref","first-page":"32952","DOI":"10.1074\/jbc.M114.610998","article-title":"Structures of human steroidogenic cytochrome P450 17A1 with substrates","volume":"289","author":"Petrunak","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.taap.2024.116945_bb0315","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1124\/dmd.117.075317","article-title":"Structural and functional evaluation of clinically relevant inhibitors of steroidogenic cytochrome P450 17A1","volume":"45","author":"Petrunak","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.taap.2024.116945_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.102999","article-title":"Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site","volume":"299","author":"Petrunak","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"15_suppl","key":"10.1016\/j.taap.2024.116945_bb0325","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1200\/JCO.2020.38.15_suppl.5064","article-title":"Immunomodulation by HDAC inhibition: results from a phase I study with entinostat in combination with atezolizumab and bevacizumab in metastatic renal cell carcinoma patients","volume":"38","author":"Pili","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.taap.2024.116945_bb0330","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1023\/A:1013185402896","article-title":"Result of two randomized trials comparing nolatrexed (ThymitaqTM) versus methotrexate in patients with recurrent head and neck cancer","volume":"12","author":"Pivot","year":"2001","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.taap.2024.116945_bb0335","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel Steroidal Inhibitors of Human Cytochrome P45017\u03b1 (17\u03b1-Hydroxylase-C17,,20-lyase): Potential Agents for the Treatment of Prostatic Cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.taap.2024.116945_bb0340","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.bmcl.2014.04.024","article-title":"Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors","volume":"24","author":"Rafferty","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.taap.2024.116945_bb0345","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejmech.2016.05.047","article-title":"Inside HDACs with more selective HDAC inhibitors","volume":"121","author":"Roche","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0350","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1210\/jcem-57-4-732","article-title":"Site of action of low dose ketoconazole on androgen biosynthesis in men","volume":"57","author":"Santen","year":"1983","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.taap.2024.116945_bb0355","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/BF02307090","article-title":"Phase I\/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate","volume":"2","author":"Seidmon","year":"1995","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.taap.2024.116945_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104240","article-title":"History of the development of antifungal azoles: a review on structures, SAR, and mechanism of action","volume":"104","author":"Shafiei","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0365","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1747-0285.2005.00327.x","article-title":"Use of an induced fit receptor structure in virtual screening","volume":"67","author":"Sherman","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"issue":"5","key":"10.1016\/j.taap.2024.116945_bb0370","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1517\/17425255.4.5.513","article-title":"Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450","volume":"4","author":"Stjernschantz","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"19","key":"10.1016\/j.taap.2024.116945_bb0375","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-11-1101","article-title":"A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors","volume":"17","author":"Tabernero","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8400","key":"10.1016\/j.taap.2024.116945_bb0380","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(84)92909-X","article-title":"Ketoconazole therapy for advanced prostate Cancer","volume":"324","author":"Trachtenberg","year":"1984","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.taap.2024.116945_bb0385","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.bmc.2005.06.009","article-title":"DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors","volume":"13","author":"Vanommeslaeghe","year":"2005","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0390","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/00325481.1983.11698312","article-title":"Oral antifungal therapy. Current status of ketoconazole","volume":"73","author":"Varkey","year":"1983","journal-title":"Postgrad. Med."},{"issue":"1\u20132","key":"10.1016\/j.taap.2024.116945_bb0395","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","article-title":"CYP17 inhibitors for prostate cancer therapy","volume":"125","author":"Vasaitis","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0400","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/prot.10465","article-title":"Improved protein-ligand docking using GOLD","volume":"52","author":"Verdonk","year":"2003","journal-title":"Proteins Struct. Funct. Genet."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0405","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14787210.2021.1939011","article-title":"Efinaconazole topical solution (10%) for the treatment of onychomycosis in adult and pediatric patients","volume":"20","author":"Vlahovic","year":"2022","journal-title":"Expert Rev. Anti-Infect. Ther."},{"issue":"22","key":"10.1016\/j.taap.2024.116945_bb0410","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJM198405313102202","article-title":"Inhibition of adrenal steroidogenesis by the anesthetic etomidate","volume":"310","author":"Wagner","year":"1984","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.taap.2024.116945_bb0415","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002800050422","article-title":"AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies","volume":"37","author":"Webber","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2024.116945_bb0420","article-title":"DrugBank: a comprehensive resource for in silico drug discovery and exploration","volume":"34(Database issue):D668\u201372","author":"Wishart","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.taap.2024.116945_bb0425","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"3\u20135","key":"10.1016\/j.taap.2024.116945_bb0430","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.taap.2024.116945_bb0435","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17: established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.taap.2024.116945_bb0440","doi-asserted-by":"crossref","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin. Hypertens."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:12:02Z","timestamp":1777396322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X24001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":88,"alternative-id":["S0041008X24001431"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.116945","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.116945","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116945"}}